Long-Term Real-World Efficacy Outcomes of Natalizumab vs Fingolimod in RRMS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Frontiers in Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
Front Neurol 2021 Oct 01;12(xx)699844, M Boziki, C Bakirtzis, V Giantzi, SA Sintila, S Kallivoulos, T Afrantou, I Nikolaidis, P Ioannidis, T Karapanayiotides, I Koutroulou, D Parissis, N GrigoriadisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.